Curative (company)

EN Texto em inglês Ainda não há artigo no seu idioma: trecho em inglês.

Curative Inc. is a United States-based health insurance company headquartered in Austin, Texas. In September 2022, it launched Curative Insurance Company, an employer-based health plan that is structured with a single monthly premium and is marketed as having no copayments and no deductibles for covered services within its network. Curative was founded in January 2020 and initially developed diagnostic tools before pivoting to COVID-19 testing and vaccination operations during the COVID-19 pandemic. The company began winding down its COVID-19 testing business in 2022 and transitioned its operations to focus on health insurance in 2023. In January 2020, Fred Turner, Isaac Turner (no relation), and Vlad Slepnev co-founded Curative, Inc. to create new diagnostic tools for the detection and management of sepsis. In response to nationwide (US) shortages of diagnostic test kits, laboratory testing capacity, and personal protective equipment (PPE) available to healthcare workers, the company abruptly pivoted to focus on COVID-19 in March 2020. Curative developed a self-collected oral fluid swab as an alternative sample collection method, an orthogonal supply chain approach to avoid competing with other SARS-CoV-2/COVID-19 test kit and laboratory analysis providers, created the Curative SARS-CoV-2 Assay, and began field tests using supervised self-collection in Los Angeles and Long Beach (California) in March. In early April, Curative contacted UK government officials, offering to supply 50,000 test kits per week. The company's novel RT-PCR-based Curative SARS-CoV-2 Assay received FDA Emergency Use Authorization (EUA) in April 2020. Later in April 2020, the United States Department of Defense signed a US$13M agreement with Curative to source Curative SARS-CoV-2 Assay kits for Air Force use, to establish a new laboratory facility with testing capacity of 50,000 tests per day within one week of signing, and to establish additional test locations across the US at a later date.